Due to its insurability and significant neurologic morbidity, glioblastoma is the most prevalent and aggressive primary brain tumour in adults and adds to the high social and medical burden. The survival rate for Recurrent Glioblastoma Multiforme Treatment has not increased in spite of ongoing research. This review discusses the most recent developments in clinically significant molecular profiling, such as IDH mutation status and MGMT promoter methylation.
We discuss recent developments in the treatment of newly diagnosed and recurrent glioblastoma as well as typical management challenges like pseudoprogression and pseudoresponse. A brief discussion of ongoing targeted therapy and immunotherapy translational research is provided.
Read More:
https://bloggerthrive.blogspot.com/2023/01/recurrent-glioblastoma-multiforme.html
